Key result
Transcutaneous vagus nerve stimulation cuts central aortic systolic pressure ~12 mmHg vs sham in acute HF.
Why the study?
Reduction of central blood pressure decreases LV afterload and may prevent HF decompensation, prompting investigation into whether active tVNS reduces central BP in acute HF.
Does active transcutaneous vagus nerve stimulation reduce central aortic systolic pressure and afterload in patients with acute heart failure?
RCT (n=22)
Double-blind
1:1
No
Does active transcutaneous vagus nerve stimulation reduce central aortic systolic pressure and afterload in patients with acute heart failure?
Absolute Event Rate: -11.5% vs 8.37%
p-value: p=0.0003
Non-invasive transcutaneous vagus nerve stimulation acutely reduces central aortic systolic pressure and afterload in elderly patients with acute heart failure.
Offers non-invasive afterload reduction in acute heart failure; extends vagus nerve stimulation evidence to acute settings.
Introduction While central blood pressure (BP) has been recognized as a major indicator of left ventricular (LV) afterload, the reduction of central pressure decreases LV afterload and may prevent heart failure (HF) decompensation. Non-invasive transcutaneous vagus nerve stimulation (tVNS) was shown to improve cardiac function in HF patients. In this study, the relationship between active tVNS and reduction of central BP was investigated in patients with acute HF (AHF). Methods The 22 patients hospitalized for AHF after initial stabilization (median 80 yrs, males 60%) were randomly assigned to active or sham group. For 1 h daily over 5 days, low-level transcutaneous electrical stimulation (LLTS) (20 Hz, 1 mA) was performed after attaching an ear clip to the tragus (active group) or the earlobe (sham control group). Before and after stimulation, central aortic systolic pressure (CASP), brachial systolic BP (SBP), diastolic BP (DBP) as well as heart rate (HR) were noninvasively measured. Results No significant differences in baseline characteristics were observed between the active and sham groups. In the active group, CASP, SBP, DBP, and HR each decreased significantly after stimulation (all p < 0.05), whereas in the sham group, CASP, SBP, DBP, and HR each increased significantly after stimulation (all p < 0.05). All the changes in CASP, SBP, DBP and HR before and after stimulation were also significantly different between active and sham groups (all p < 0.01). There were no device-related side effects. Conclusion In this study, the left tragus tVNS resulted in an acute afterload reduction in the elderly AHF patients. Non-invasive LLTS may be useful and safe for reducing afterload in AHF. Clinical trial registration ClinicalTrials.gov , identifier UMIN000044121.
No takes yet. Share an insight, caveat, or question.
Nagai et al. (2023) conducted an RCT in Acute heart failure (n=22). Active transcutaneous vagus nerve stimulation (tVNS) at the left tragus vs. Sham stimulation at the left earlobe was evaluated on Change in central aortic systolic pressure (CASP) (p=0.0003). Active transcutaneous vagus nerve stimulation significantly reduced central aortic systolic pressure by a median of 11.5 mmHg compared to sham stimulation in patients with acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: